United Therapeutics (UTHR) Accumulated Expenses (2009 - 2025)

United Therapeutics (UTHR) has 17 years of Accumulated Expenses data on file, last reported at $480.9 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses rose 42.07% year-over-year to $480.9 million; the trailing twelve-month figure through Dec 2025 stood at $480.9 million (up 42.07% YoY), and the FY2025 full-year result was $480.9 million, up 42.07% from the prior year.
• Accumulated Expenses rose to $480.9 million in Q4 2025, from $338.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $480.9 million in Q4 2025 to a low of $170.8 million in Q4 2021.
• A 5-year average of $301.7 million and a median of $292.4 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses fell 6.62% in 2021 and surged 42.07% in 2025, its largest moves.
• Tracing UTHR's Accumulated Expenses over 5 years: stood at $170.8 million in 2021, then soared by 32.2% to $225.8 million in 2022, then grew by 29.5% to $292.4 million in 2023, then advanced by 15.77% to $338.5 million in 2024, then surged by 42.07% to $480.9 million in 2025.
• Business Quant data shows UTHR's Accumulated Expenses at $480.9 million in Q4 2025, $338.5 million in Q4 2024, and $292.4 million in Q4 2023.